Editorial: Analysis of tumor immune microenvironments and molecular mechanism to reveal the dilemma of immunotherapy for advanced non-small cell lung cancer.
作者信息
Roviello Giandomenico, Vascotto Ismaela Anna, Catalano Martina
机构信息
Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
School of Human Health Sciences, University of Florence, Florence, Italy.
出版信息
Front Immunol. 2024 Apr 25;15:1415608. doi: 10.3389/fimmu.2024.1415608. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Analysis of tumor immune microenvironments and molecular mechanism to reveal the dilemma of immunotherapy for advanced non-small cell lung cancer.社论：分析肿瘤免疫微环境及分子机制以揭示晚期非小细胞肺癌免疫治疗困境
Front Immunol. 2024 Apr 25;15:1415608. doi: 10.3389/fimmu.2024.1415608. eCollection 2024.
2
Lung cancer: potential targets for immunotherapy.肺癌：免疫治疗的潜在靶点。
Lancet Respir Med. 2013 Sep;1(7):551-63. doi: 10.1016/S2213-2600(13)70159-0. Epub 2013 Aug 23.
3
Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.化疗诱导的非小细胞肺癌免疫调节：联合化疗免疫疗法的理论依据
Immunotherapy. 2017 Sep;9(11):913-927. doi: 10.2217/imt-2017-0052.
4
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.免疫检查点抑制剂联合化疗治疗非小细胞肺癌的分子基础和原理。
Drug Resist Updat. 2019 Sep;46:100644. doi: 10.1016/j.drup.2019.100644. Epub 2019 Sep 17.
5
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.非小细胞肺癌中靶向治疗和免疫治疗的耐药机制：克服挑战的有前景策略
Front Immunol. 2024 Apr 9;15:1366260. doi: 10.3389/fimmu.2024.1366260. eCollection 2024.
6
[Immunotherapy in non-small cell lung cancer patients: back to the future.].[非小细胞肺癌患者的免疫治疗：回归未来。]
Recenti Prog Med. 2019 Dec;110(12):587-593. doi: 10.1701/3278.32517.
7
Immunotherapy in the treatment of non-small cell lung cancer.免疫疗法在非小细胞肺癌治疗中的应用。
Klin Onkol. 2021 Spring;34(Supplementum 1):54-64. doi: 10.48095/ccko2021S54.
8
Targeting Immunometabolism Mediated by CD73 Pathway in -Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance.针对 CD73 通路介导的 - 突变型非小细胞肺癌的免疫代谢靶向治疗：克服免疫耐药性的新希望。
Front Immunol. 2020 Jul 14;11:1479. doi: 10.3389/fimmu.2020.01479. eCollection 2020.
9
[Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer].[非小细胞肺癌中免疫检查点抑制剂的预测生物标志物]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 12;43(2):87-91. doi: 10.3760/cma.j.issn.1001-0939.2020.02.004.
10
Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.机器学习揭示了基于基因表达背景的非小细胞肺癌免疫治疗反应的 PD-L1 独立预测。
Eur J Cancer. 2020 Nov;140:76-85. doi: 10.1016/j.ejca.2020.09.015. Epub 2020 Oct 12.
本文引用的文献
1
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance.癌症中免疫检查点阻断耐药的全景：潜在机制和克服耐药的当前策略。
Cancer Biol Ther. 2024 Dec 31;25(1):2308097. doi: 10.1080/15384047.2024.2308097. Epub 2024 Feb 2.
2
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗 NSCLC 患者血浆中可溶性 PD-1 和 PD-L1 的临床作用。
Cancer Immunol Immunother. 2023 Aug;72(8):2829-2840. doi: 10.1007/s00262-023-03464-w. Epub 2023 May 16.
3
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.治疗前可溶性 PD-L1 作为免疫检查点抑制剂治疗总生存期的预测因子：系统评价和荟萃分析。
Cancer Immunol Immunother. 2023 May;72(5):1061-1073. doi: 10.1007/s00262-022-03328-9. Epub 2022 Nov 16.
4
Immune Checkpoint Inhibitors in Cancer Therapy.癌症治疗中的免疫检查点抑制剂。
Curr Oncol. 2022 Apr 24;29(5):3044-3060. doi: 10.3390/curroncol29050247.
5
Neoadjuvant immunotherapy facilitates resection of surgically-challenging lung squamous cell cancer.新辅助免疫疗法有助于切除具有手术挑战性的肺鳞状细胞癌。
J Thorac Dis. 2021 Dec;13(12):6816-6826. doi: 10.21037/jtd-21-1195.
Zotero 插件